Descrizione del progetto
Razionalizzazione dell’innovazione attraverso la produzione automatizzata di immunoterapie altamente selettive
Il sistema immunitario è un team complesso che mira a distruggere i patogeni e ad aiutare il corpo a eliminare le cellule danneggiate o quelle anomale quali le cellule tumorali. Gli anticorpi si attaccano agli antigeni, i marker presenti sulla superficie delle cellule bersaglio, facendo sapere agli altri elementi del team di venire in soccorso. Gli anticorpi monoclonali (MAb, Monoclonal AntiBodies) sono anticorpi prodotti in laboratorio con una specificità molto elevata ottenuta dalla fusione di cellule produttrici di anticorpi con una linea cellulare immortale. Sebbene i tipi di MAb disponibili stiano rapidamente aumentando, il processo di separazione per garantirne la purezza è ancora eseguito manualmente. iSTantibody sta rivoluzionando questo processo con una piattaforma automatizzata che promette di ridurre drasticamente i tempi di produzione e di liberare scienziati altamente qualificati per ricercare e sviluppare ancora più terapie.
Obiettivo
Therapeutic monoclonal antibodies (mAbs) are innovative therapeutic tools that are currently drawing the attention of biopharma companies for their effectiveness against a broad panel of diseases. To guarantee safety for patients, tight control over the purity of mAbs preparations is crucial. The presence of contaminants in mAbs preparations can be assessed using mass spectrometry (MS), a technique characterised by remarkable sensitivity, but which requires a time-consuming, complicated and poorly reproducible sample preparation. Notably, at today’s date, this process cannot be automated or multiplexed: it has to be performed by highly skilled scientific staff, and - importantly - it cannot be easily “plugged in” the streamlined production approaches of pharma companies. PreOmics is a young German company seeking to revolutionise the MS proteomics market with its proprietary technology portfolio. Through the iSTantibody project, PreOmics translates its patented iST technology in the context of mAbs MS analysis and tackles the current pitfalls of mAbs sample preparation. Its final goal consists of a kit to simplify and shorten MS sample preparation by > 95% compared to standard protocols, eliminating the need for skilled scientists and allowing MS sample purification on automated liquid handling platforms. The advantages for potential customers are manifold – notably, significantly reduced costs, and the consequent possibility to free resources for mAbs development. The target sector of iSTantibody is the ever-growing market for MS sample preparation consumables, which is forecasted to reach a volume of € 1.3 billion worldwide in 2022, at a CAGR of 12%. The benefit of the iSTantibody project will produce remarkable benefits for PreOmics, both in terms of increased revenues (+ € 15.3 million in 2026), employability (creation of 13 jobs) and innovation potential, opening new market perspectives and allowing PreOmics to seize more opportunities in the years ahead.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
82152 PLANEGG MARTINSRIED
Germania
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.